Literature DB >> 1507350

Urinary tract status of patients with neurogenic dysfunction presenting with upper tract stone disease.

J Wan1, S Fleenor, P Kielczewski, E J McGuire.   

Abstract

We treated 71 patients with neurogenic vesical dysfunction between September 1983 and June 1990 for upper tract stones. We studied these patients to determine the time course of stone development and the presence of associated urological abnormalities. There were 44 male and 27 female patients 6 to 72 years old. Lower urinary tract dysfunction resulted from spinal cord injuries in 34 patients (48%), myelodysplasia in 19 (27%), multiple sclerosis in 12 (17%) and other diagnoses in 6 (8%). Of 71 patients 21 (30%) were managed by an ileal loop, 12 (17%) by a Foley catheter, 10 (14%) by a suprapubic tube, 10 (14%) by ureterostomy, 5 (7%) by vesicostomy, 8 (11%) by intermittent catheterization, and 5 (7%) by diaper, Créde's voiding or condom catheterization. Stone disease developed within 1 to 22 years. Patients with an indwelling catheter or supravesical diversion fared worse than those managed by intermittent catheterization or vesicostomy; they had higher rates of renal unit loss, renal parenchymal damage, decreased renal function, hydroureter, and staghorn and bilateral calculi. All of the listed methods of management were contemporaneous, suggesting the continued use of methods proved to be associated with upper tract deterioration.

Entities:  

Mesh:

Year:  1992        PMID: 1507350     DOI: 10.1016/s0022-5347(17)36838-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Retrograde intrarenal surgery by flexible ureteroscope in patients with spinal deformities.

Authors:  Fazli Polat; Suleyman Yesil
Journal:  J Spinal Cord Med       Date:  2016-02-23       Impact factor: 1.985

2.  Urolithiasis in adult spina bifida patients: study in 260 patients and discussion of the literature.

Authors:  Paul W Veenboer; J L H Ruud Bosch; Floris W A van Asbeck; Laetitia M O de Kort
Journal:  Int Urol Nephrol       Date:  2013-04-19       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.